| Title： | Expert Consensus on Clinical Application of Integrin RGD Receptor Imaging (2022) |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Diagnosis |
| Countries and regions： | China |
| Guidelines users： | Doctors who recommend patients to perform integrin RGD receptor imaging to diagnose the disease. |
| Evidence classification method： | This consensus mainly includes two types of evidence: First, high-level evidence-based medical evidence (Category 1), which is unanimously agreed by the expert group and strongly recommended (A); Second, the level of evidence is slightly lower (Category 2), but the expert group basically agrees, and it is moderately recommended (B). Other levels of evidence will not be currently included. |
| Development unit： | Chinese Society of Nuclear Medicine, Chinese Society of Molecular |
| Registration time: | 2022-03-23 |
| Registration number： | IPGRP-2022CN166 |
| Purpose of the guideline: | Based on the home-and-abroad progress in relevant clinical research, this expert consensus aims to establish principles for clinical application of RGD-based peptides for integrin imaging. |
Latest registration
